Hopp til hovedinnhold

Irritabel tarm-syndrom

Sist oppdatert: Sist revidert:
Sist revidert av:


Definisjon:
Kronisk, funksjonell tilstand i nedre GI-traktus karakterisert ved smerter eller ubehag i magen, og forstoppelse eller diarè, eller vekslinger mellom disse. Årsaken er ukjent.
Forekomst:
En norsk studie fant prevalens på 8%, men ulike diagnostiske kriterier gjør tall for insidens og prevalens usikre
Symptomer:
Tilstanden er kjennetegnet av magesmerter og ubehag, oppblåsthet og et forstyrret avføringsmønster. Noen har vekslende diaré og forstoppelse, andre er dominert av enten diaré eller forstoppelse. Felles er lindring av symptomene ved luftavgang og avføring
Funn:
Hos de fleste avdekkes ingen unormale funn ved undersøkelsen
Diagnostikk:
Det finnes ingen spesifikke diagnostiske tester
Behandling:
Psykologisk intervensjon i form av en positiv symptombasert diagnose, beroligelse, identifisering av psykososiale problemer og forklaring av symptomer. Diettintervensjoner eller medikamentell behandling kan være aktuelt
  • Nasjonal kompetansetjeneste for funksjonelle mage-tarmsykdommer - nettside 
  1. Snyder N. Irritable bowel syndrome. BMJ Best Practice, last reviewed 22 Nov 2021. bestpractice.bmj.com  
  2. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017 Jun 29;376(26):2566-2578. PMID: 28657875.
  3. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491. PubMed  
  4. Vandvik, P. O. and Lydersen S, Farup PG. Prevalence, impact and comorbidity of IBS in Norway. Scand J Gastroenterol 2006; 41: 650-6. PubMed  
  5. Johansen SG, Ness-Jensen E. The changes in prevalence and risk of irritable bowel syndrome over time in a population-based cohort, the HUNT study, Norway. Scand J Gastroenterol. 2022 Feb 4:1-7. Epub ahead of print. PMID: 35119352. PubMed  
  6. Agrawal A, Houghton LA, Reilly B, et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009; 104:1998. PubMed  
  7. Lehrer JK. Irritable bowel syndrome. Medscape, last updated Apr 04, 2017. emedicine.medscape.com  
  8. Lawal A, Kern M, Sidhu H, et al. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006; 130:26. Gastroenterology  
  9. Dorn SD, Palsson OS, Thiwan SI, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56:1202. Gut  
  10. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107: 1898-906. PubMed  
  11. Ford AC, Vandvik PO. Irritable bowel syndrome: dietary interventions. Systematic review 410. BMJ Clinical Evidence 2015.
  12. Rej A, Sanders DS. Gluten-free diet and its ‘cousins’ in irritable bowel syndrome. Nutrients. 2018 Nov; 10(11): 1727. www.ncbi.nlm.nih.gov  
  13. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of Gastroenterology and Hepatology 2010; 25: 252-8. PubMed  
  14. Berstad A, Valeur J, Lillestøl K, et al, Matoverfølsomhet – et paradigmeskifte?, Allergi i praksis, 1/2011.
  15. Melchior C, Gourcerol G, Dechelotte P, et al. Symptomatic fructose malasorption in irritable bowel syndrome: A prospective study. Un Eur Gastroenterol J 2014; 2: 131-7. doi: 10.1177/2050640614521124 DOI  
  16. Gibson PR, Newnham E, Barrett JS, Shepherd SJ, Muir JG. Review article: fructose malabsorption and the bigger picture. Aliment Pharmacol Ther 2007; 25: 349-63. PubMed  
  17. Thabane M, et al. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-44. PubMed  
  18. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:956-62.e1. PMID: 23357491.
  19. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil 2017; 23 (2): 151-63.
  20. Cristofori F, Fontana C, Magista A, et al. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome. A 6-year prospective chort study. JAMA Pediatr 2014. doi:10.1001/jamapediatrics.2013.4984 DOI  
  21. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity. Am J Gastroenterol, 2012. doi:10.1038/ajg.2012.236 DOI  
  22. Rostom A, Dubé C, Cranney A, et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 2005; 128 (4 Suppl 1): 38-46.
  23. Waugh N, Cummins E, Royle P, et al. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritiable bowel syndrome. Ann Intern Med 2014; 160: JC13. doi:10.7326/0003-4819-160-8-201404150-02013 DOI  
  24. Menees SB, Powell C, Kurlander J, et al. A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS. Am J Gastroenterol 2015; 110: 444-54. doi:10.1038/ajg.2015.6 DOI  
  25. Maagaard L, Ankersen DV, Vegh Z, et al. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol 2016; 22: 4009-19. pmid:27099444 PubMed  
  26. Black CJ, Staudacher HM, Ford AC Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2021. PMID: 34376515 PubMed  
  27. NICE guideline. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. NICE guideline CG61, 2015.
  28. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-158. PubMed  
  29. Nurko S, Saps M, Kossovsky J, et al. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome A Randomized Clinical Trial. JAMA Pediatr 2022. doi:10.1001/jamapediatrics.2021.5750 DOI  
  30. El-Salhy M, Hatlebakk JG, Gilja OH et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 2019. Epub ahead of print. pmid:31852769 PubMed  
  31. Everitt HA, Landau S, O'Reilly G, et al. Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut, published online first: 10 April 2019. gut.bmj.com  
  32. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58. doi: 10.1001/jama.2015.0954 DOI  
  33. Robinson A, Lee V, Kennedy A, et al. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006; 55: 643-8. Gut  
  34. Staudacher HM1, Whelan K, et.al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet, Oct 2011; 24(5): 487-95.
  35. Halmos E, Power V, et.al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75. Gastroenterology  
  36. Dionne J, Ford AC, Yuhong Y et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol 2018. pmid:30046155 PubMed  
  37. Carbone F, Van den Houte K, Besard L et al. DOMINO Study Collaborators; Domino Study Collaborators. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 Apr 28:gutjnl-2021-325821. Epub ahead of print. PMID: 35483886 PubMed  
  38. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109:Suppl 1:S2-S26. PMID: 25091148. PubMed  
  39. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014 Sep;109(9):1367-74. PMID: 25070054 PubMed  
  40. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Soluble og insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154. BMJ (DOI)  
  41. Moayyedi P, Ford AC, Talley NJ, et al.The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32. Gut  
  42. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012 Sep 18. pmid:22986440 PubMed  
  43. Shah ED, Kim HM, Schoenfeld P. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018. PMID: 29380823 PubMed  
  44. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014 Oct; 109:1547 doi:10.1038/ajg.2014.202 DOI  
  45. Layer P, Stanghellini V. Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014; 39: 371-84. PubMed  
  46. Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology 2022; 163: 118-136. pmid:35738724 PubMed  
  47. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012 Sep 18. pmid:22986437 PubMed  
  48. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018. pmid:29545635 PubMed  
  49. Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014; 39: 239-53. pmid: 24308797 PubMed  
  50. Chey WD, Lembo AJ, Rosenbaum DP Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am J Gastroenterol. 2020. PMID: 31934897 PubMed  
  51. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD003460. DOI: 10.1002/14651858.CD003460.pub3. Accessed 15 July 2022. The Cochrane Library  
  52. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology 2022; 163: 137-151. pmid:35738725 PubMed  
  53. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016: 150: 358-66. PMID: 26551550 PubMed  
  54. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014; 48: 505-12. pmid:24100754 PubMed  
  55. Nee J, Ballou S, Kelley JM, et al. Peppermint oil treatment for irritable bowel syndrome: A randomized placebo-controlled trial. Am J Gastroenterol 2021. PMID: 34319275 PubMed  
  56. Statens Legemiddelverk (SLV). Nye anbefalinger ved bruk av metoklopramid. Juli 2013.
  57. Liu JP, Yang M, Liu Y, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004116. DOI: 10.1002/14651858.CD004116.pub2. DOI  
  58. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2013 Dec 12.
  59. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-7. Gut  
  60. Tazzyman S, Richards N, Trueman AR, et al. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. BMJ Open Gastro 2015; 2:e000052 . doi:10.1136/bmjgast-2015-000052 DOI  
  61. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003. PubMed  
  62. van der Veek PP, van Rood YR, Masclee AA. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 943-52. PubMed  
  63. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
  64. Halkjær SI, Christensen AH, Lo BZS, et al Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study Gut Published Online First: 06 July 2018.
  65. Canavan C, West J, Card T. The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023-1034. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Per Olav Vandvik, kst. overlege og dr. med., Medisinsk avdeling, Sykehuset Innlandet HF, Gjøvik og førsteamanuensis ved Universitetet i Oslo